ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

NVX-CoV2373 adjuvated lipid nanoparticle

Also written as “NVX-CoV2373”, “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)” and “NVX-Cov2373”.

Its studies are mostly in COVID-19 · Severe Acute Respiratory Syndrome, led by 4 companies.

Drug pageNVX-CoV2373 adjuvated lipid nanoparticle: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 4, 202416 company-led studies, 1 open or runningNext primary completion: Nov 26, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novavax120 open or runningphase 4since Oct 4, 2024Apr 24, 2020none ahead
Takedaits history only20 open or runningphase 3since Mar 27, 2022Jan 14, 2021none ahead
Cogna Technology Solutionsits history only10 open or runningphase 3since Feb 18, 2022Feb 18, 2022none ahead
Sanofiits history only11 open or runningphase 4since Sep 30, 2026Sep 30, 2026Nov 26, 2026phase 4 · NCT07861542

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novavax only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2020First study: phase 2 study in COVID-19First studyNCT04368988 · 1,419 enrolled · United States, Australia
  2. Aug 28, 2020Phase 2 study in COVID-19NCT04533399 · 4,422 enrolled · South Africa
  3. Oct 9, 20202 phase 3 studiesNCT04583995, NCT04611802
  4. Oct 25, 2021Phase 2 study in COVID-19NCT05112848 · 384 enrolled · South Africa
  5. May 9, 2022Phase 3 study in COVID-19NCT05372588 · 1,340 enrolled · Australia
  6. Jul 14, 20222 phase 3 studies in COVID-19NCT05463068, NCT05468736
  7. May 16, 2023Phase 3 study in COVID-19NCT05875701 · 147 enrolled · United States
  8. Jun 27, 2023Phase 3 study in COVID-19NCT05925127 · 994 enrolled · United States
  9. Mar 1, 2024Phase 3 study in COVID-19NCT06291857 · 9,320 enrolled · Australia, New Zealand
  10. Oct 4, 2024Phase 4 study in COVID-19NCT06633835 · 660 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 12 Novavax leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06633835COVID-19 · United States4CompletedDec 30, 2024660
NCT06291857COVID-19 · Australia, New Zealand3CompletedDec 24, 20259,320
NCT05925127COVID-19 · United States3CompletedMay 21, 2024994
NCT05875701COVID-19 · United States3CompletedNov 11, 2023147
NCT05468736COVID-19 · United States, Colombia, Dominican Republic and more3CompletedJan 16, 20243,600
NCT05463068COVID-19 · United States3CompletedAug 17, 2022911
NCT05372588COVID-19 · Australia3CompletedJul 17, 20221,340
NCT05112848COVID-19 · South Africa2CompletedMay 23, 2022384
NCT04611802Severe Acute Respiratory Syndrome · United States, Mexico, Puerto Rico3CompletedApr 10, 202333,000
NCT04583995COVID-19 · United Kingdom3CompletedMar 29, 202215,185
NCT04533399COVID-19 · South Africa2CompletedDec 7, 20214,422
NCT04368988COVID-19 · United States, Australia2CompletedJun 1, 20221,419

How it is read

Names in the registry

  • “NVX-CoV2373”, 3 entries
  • “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)”, 2 entries
  • “NVX-Cov2373”, 2 entries
  • “TAK-019”, 2 entries
  • “Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.